Posted by Michael Wonder on 17 Nov 2025
FDA grants fast track designation to Dewpoint Therapeutics’ DPTX3186 for the treatment of gastric cancer
17 November 2025 - Dewpoint Therapeutics announced today that the US FDA has granted fast track designation to DPTX3186, the company’s first in class oral condensate modulator targeting the Wnt/β-catenin pathway, for the treatment of gastric cancer.
DPTX3186 is a first in class small molecule designed to modulate the oncogenic function of β-catenin, a central driver of gastric cancer and multiple other solid tumours.
